DAXOR CORPORATION - CLOSED END FUND

Daxor Corporation to Exhibit at the 45th International Society for Heart and Lung Transplant (ISHLT) Annual Meeting and Scientific Sessions

22 Apr 2025 06:59:59 By Nasdaq GlobeNewswire

Daxor Corporation to Showcase Innovative Blood Volume Analysis at MedAxiom Cardiovascular Transforum Spring 2025

17 Apr 2025 07:00:00 By Nasdaq GlobeNewswire

New Research at ACC25 Shows Daxor BVA-Identified Euvolemic Heart Failure Patients Experience 2.61 Times Better Survival

15 Apr 2025 07:00:00 By Nasdaq GlobeNewswire

Daxor Corporation Submits 510(k) to FDA for Next-Generation Blood Volume Analyzer

10 Apr 2025 07:00:00 By Nasdaq GlobeNewswire

Daxor Corporation Announces New Data from Duke University and Highlights Key BVA Insights at American College of Cardiology’s 74th Annual Scientific Session and Expo

02 Apr 2025 07:00:00 By Nasdaq GlobeNewswire

Daxor Expands Blood Volume Analysis Technology Across Midwest, Wisconsin, and New Jersey Healthcare Networks

28 Mar 2025 07:00:00 By Nasdaq GlobeNewswire

Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2024

04 Mar 2025 15:55:00 By Nasdaq GlobeNewswire

Daxor Corporation to Host Investor Conference Call to Discuss Fiscal Year 2024 Financial Results and Provide a Corporate Update on March 6, 2025

04 Mar 2025 14:53:00 By Nasdaq GlobeNewswire

Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders

04 Mar 2025 08:00:00 By Nasdaq GlobeNewswire

Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders

04 Mar 2025 07:05:00 By Nasdaq GlobeNewswire

Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023

04 Mar 2025 07:00:00 By Nasdaq GlobeNewswire

Daxor Expands Blood Volume Analysis Services at Major Midwest Healthcare Center

28 Feb 2025 07:00:00 By Nasdaq GlobeNewswire

Daxor Corporation Expands Blood Volume Analysis Technology to Major New Jersey Hospitals

27 Feb 2025 07:00:00 By Nasdaq GlobeNewswire

Daxor Corporation Announces New Data on Blood Volume Analysis from Duke and Yale Universities Presented at THT 2025

19 Feb 2025 07:00:00 By Nasdaq GlobeNewswire

Daxor to Exhibit at World's Largest Critical Care Conference

18 Feb 2025 07:00:00 By Nasdaq GlobeNewswire

Daxor's Blood Volume Analysis Uncovers Hidden Heart Failure Subtype in Nearly 1 in 5 Patients, Enabling Targeted Treatment

14 Feb 2025 07:00:00 By Nasdaq GlobeNewswire

New Multicenter Study Highlights Utility of Daxor’s Blood Volume Analysis in Heart Failure Care

13 Feb 2025 07:00:00 By Nasdaq GlobeNewswire

Daxor Expands Its BVA-100™ Blood Volume Diagnostic to Two New Hospital Systems Adding to Sales Momentum

18 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

DAXOR'S INNOVATIVE BVA-100™ BLOOD VOLUME DIAGNOSTIC FEATURED AT MEDAXIOM CV TRANSFORUM FALL '24

09 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Daxor Corporation to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

08 Oct 2024 07:00:00 By Nasdaq GlobeNewswire